MedTrace Logo

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

NCT03452527 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2021-04-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients with wet macular degeneration.

Conditions

  • Choroidal Neovascularization
  • Wet Macular Degeneration

Interventions

BIOLOGICAL

ICON-1

ICON-1 0.6 mg by intravitreal injection

BIOLOGICAL

aflibercept

aflibercept 2 mg by intravitreal injection

Sponsors & Collaborators

  • Iconic Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Gabriela Burian, MD · Iconic Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-26
Primary Completion
2019-04-25
Completion
2019-04-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03452527 on ClinicalTrials.gov